Insider · CIK 0001919170
Coleen Glessner
Files at EBS (Emergent BioSolutions Inc.). First filing Oct 16, 2025, latest Oct 16, 2025.
Coleen Glessner files SEC Form 4 as officer at EBS (Emergent BioSolutions Inc.). Since Oct 16, 2025, Coleen Glessner has reported 0 open-market buys worth $0 and 1 open-market sell worth $306k, the latest filed on Oct 16, 2025.
A track record needs three past buys with six months of prices behind them; Coleen Glessner has 0, so none is measured yet.
The newest scored trade: sold $306k of EBS on Oct 7, 2025, filed Oct 16, 2025, scored 14 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $306k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
EBS: Emergent BioSolutions Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 14Weak | Emergent BioSolutions Inc. | $306k 30,608 shares | -17% | +133% from low-17% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Oct 7, 2025 | EBS EMERGENT BIOSOLUTIONS INC. | 30,608 0.06% of outstanding | $306k | Oct 7, 2025 | none |
Transactions
Every row this insider has filed, 16 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 8, 2026 | EBS Emergent BioSolutions Inc. | FTax withholding Common Stock | -2,018 | $8.00 | $16k | 202,201 | Jun 10, 2026 |
| Apr 29, 2026 | EBS Emergent BioSolutions Inc. | AGrant or award Common Stock | +100,111 | $0.00 | $0 | 204,219 | May 1, 2026 |
| Mar 5, 2026 | EBS Emergent BioSolutions Inc. | FTax withholding Common Stock | -8,199 | $8.44 | $69k | 104,108 | Mar 5, 2026 |
| Mar 3, 2026 | EBS Emergent BioSolutions Inc. | AGrant or award Employee Stock Option (Right to buy)derivative | +44,834 | $0.00 | $0 | 294,447 | Mar 5, 2026 |
| Mar 1, 2026 | EBS Emergent BioSolutions Inc. | FTax withholding Common Stock | -313 | $8.15 | $2,551 | 112,307 | Mar 3, 2026 |
| Feb 6, 2026 | EBS Emergent BioSolutions Inc. | DDisposition to issuer Common Stock | -28,847 | $10.92 | $315k | 115,472 | Feb 10, 2026 |
| Feb 6, 2026 | EBS Emergent BioSolutions Inc. | FTax withholding Common Stock | -2,852 | $10.92 | $31k | 112,620 | Feb 10, 2026 |
| Oct 7, 2025 | EBS Emergent BioSolutions Inc. | SOpen-market sale Common Stock10b5-1 | -30,608 | $10.00 | $306k | 144,319 | Oct 16, 2025 |
| Jun 8, 2025 | EBS Emergent BioSolutions Inc. | FTax withholding Common Stock | -1,249 | $6.63 | $8,281 | 174,927 | Jun 10, 2025 |
| Apr 7, 2025 | EBS Emergent BioSolutions Inc. | FTax withholding Common Stock | -480 | $4.44 | $2,131 | 176,176 | Apr 9, 2025 |
| Mar 6, 2025 | EBS Emergent BioSolutions Inc. | AGrant or award Common Stock | +62,500 | $0.00 | $0 | 176,656 | Mar 10, 2025 |
| Mar 6, 2025 | EBS Emergent BioSolutions Inc. | AGrant or award Employee Stock Options (Right to Buy)derivative | +62,500 | $0.00 | $0 | 249,613 | Mar 10, 2025 |
| Feb 12, 2025 | EBS Emergent BioSolutions Inc. | DDisposition to issuer Common Stock | -5,913 | $0.00 | $0 | 138,547 | Mar 4, 2025 |
| Feb 12, 2025 | EBS Emergent BioSolutions Inc. | DDisposition to issuer Common Stock | -24,078 | $0.00 | $0 | 114,469 | Mar 4, 2025 |
| Mar 1, 2025 | EBS Emergent BioSolutions Inc. | FTax withholding Common Stock | -313 | $7.48 | $2,341 | 114,156 | Mar 4, 2025 |
| Dec 8, 2024 | EBS Emergent BioSolutions Inc. | FTax withholding Common Stock | -18,674 | $9.01 | $168k | 144,460 | Dec 10, 2024 |
Questions about Coleen Glessner
Answered from the filings on this page, as of the latest one.
Is Coleen Glessner buying or selling?
In the last 12 months Coleen Glessner reported 0 open-market buys worth $0 and 1 open-market sell worth $306k on SEC Form 4; the latest was sold $306k of EBS on Oct 7, 2025. Grants, option exercises and tax withholding are not counted.
How did Coleen Glessner's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Coleen Glessner has 0.
Where does Coleen Glessner file Form 4?
Coleen Glessner has filed Form 4 at EBS (Emergent BioSolutions Inc.) as EVP, Quality & Ethics, and CPL. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.